MARKET

BCRX

BCRX

Biocryst Pharmaceuticals Inc
NASDAQ
7.29
+0.16
+2.24%
After Hours: 7.27 -0.02 -0.27% 18:28 12/18 EST
OPEN
7.19
PREV CLOSE
7.13
HIGH
7.38
LOW
7.12
VOLUME
3.74M
TURNOVER
--
52 WEEK HIGH
11.31
52 WEEK LOW
6.00
MARKET CAP
1.53B
P/E (TTM)
-154.1226
1D
5D
1M
3M
1Y
5Y
1D
Analysts Have Conflicting Sentiments on These Healthcare Companies: BioCryst (BCRX), Wave Life Sciences (WVE) and Alkermes (ALKS)
TipRanks · 9h ago
BioCryst (BCRX) Valuation After FDA Expands ORLADEYO Access for Young Hereditary Angioedema Patients
Simply Wall St · 21h ago
The Bull Case For BioCryst (BCRX) Could Change Following FDA Approval Of Pediatric ORLADEYO Pellets
Simply Wall St · 2d ago
BioCryst Chief Legal Officer Alane P. Barnes Reports Disposal of Common Shares
Reuters · 2d ago
BioCryst Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 3d ago
BioCryst Pharmaceuticals Price Target Raised to $32.00/Share From $30.00 by HC Wainwright & Co.
Dow Jones · 3d ago
HC Wainwright & Co. Maintains Buy on BioCryst Pharma, Raises Price Target to $32
Benzinga · 3d ago
BioCryst’s Orladeyo Pediatric Approval and Strategic Expansion Drive Buy Rating
TipRanks · 3d ago
More
About BCRX
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with hereditary angioedema and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.

Webull offers BioCryst Pharmaceuticals Inc stock information, including NASDAQ: BCRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BCRX stock methods without spending real money on the virtual paper trading platform.